Foamix Pharmaceuticals Ltd. – Filings and Transcripts – BamSEC

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

SEC EDGAR

Financials Filter

ended 12/31/19 FY 2019

ended 09/30/19 Q3

ended 06/30/19 Q2

ended 03/31/19 Q1

ended 12/31/18 FY 2018

Prospectuses and Registrations Filter

Securities registration termination

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Ownership Filter

Wiley Matthew T.

Schwartz Aharon

Kazanchyan Anna

News Filter

Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019

Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Foamix and Menlo Announce Shareholder Approval of Proposed Merger

Announces AMZEEQTM (Minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S

Announces AMZEEQTM (Minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne

Proxies Filter

Additional info about upcoming vote

Additional info about upcoming vote

Proxy related to merger

Definitive proxy

Preliminary revised proxy

Other Filter

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Notice of effectiveness